COLCHICINA SEID 0,5 MG

Name: Colchicine
Presentation: 20 tablets.
Active substance: Colchicine.

Treatment for acute gout attacks and for chronic gout, prophylaxis of acute attacks at the start of treatment with uric acid mobilisers and periodic disease (familial Mediterranean fever).

MORE INFORMATION::

See the entire Colchicine Range

1 - NAME OF THE MEDICINAL PRODUCT

COLCHICINE SEID 0.5 mg tablets

2 - QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains:
Colchicine……………0.5 mg
For the full list of excipients, see section 6.1.

3 - PHARMACEUTICAL FORM

Round, biconvex, white, scored tablet.

The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.

4 - CLINICAL PARTICULARS

4.1. Therapeutic indications

Treatment for acute gout attacks and for chronic gout, prophylaxis of acute attacks at the start of treatment with uric acid mobilisers and periodic disease (familial Mediterranean fever).

4.2. Posology and method of administration

Colchicine has a narrow therapeutic index and is extremely toxic in case of overdose.

The following dose should not be exceeded under any circumstances, as it could be fatal.

Oral administration

The recommended dose depends on the patient’s age, renal and hepatic function and the concomitant use of other medications (see
sections 4.4 and 4.5).

Adults

- - - - Acute gout attack:

The recommended dose is 2 tablets (1 mg of colchicine) at the first sign of acute gout attack, followed by 1 or 2 tablets (0.5 to 1 mg of colchicine) one or two hours after the first dose. Do not administer doses of more than 2 mg of colchicine in 24 hours. Doses higher than 2 mg a day have not shown greater efficacy, but the adverse effects are increased.

This dosing regimen can be administered for up to a maximum of 4 consecutive days with a total cumulative dose of 6 mg of colchicine in 4 days. If necessary because the pain of the gout attack persists, the above-described regimen may be repeated, but always after a “wash-out period” of least 3 days without treatment.

- - - - Preventive treatment of gout attacks during initial therapy with allopurinol or uricosuric agents:

The recommended dose as preventive treatment of gout attacks is 0.5 mg of colchicine once or twice a day, which is equivalent to 1 tablet once or twice a day.

- - - - Periodic disease or familial Mediterranean fever:

The recommended dose of colchicine is 1 to 2 mg of colchicine daily. It may be administered in two daily doses or one single dose.

- - - - Treatment of chronic gout:

The recommended dose for the treatment of chronic gout is 0.5 mg to 1 mg of colchicine daily, which is equivalent to 1 tablet once or twice a day.

Children and adolescents under 18 years of age

- - - - Acute gout attack, prevention of gout attacks and chronic gout:

There are insufficient data to make recommendations for this age group.

- - - - Periodic disease or familial Mediterranean fever:

The recommended dose in children over 12 years is 1 mg (2 tablets) to 2 mg (4 tablets) daily. It may be administered in two daily doses or one single dose.

In children under 12 years, the approximate recommended dose in children aged 4 to 6 years is 0.3 mg to 1.8 mg daily and in children aged 6 to 12 years, 0.9 mg to 1.8 mg daily. These doses may be administered in one or two doses.

Renal impairment

In patients with mild renal impairment (CrCl 50-80 ml/min), no dose adjustment is required (see sections 4.4 and 5.2), although close monitoring for possible adverse effects is recommended. If adverse effects do occur, it may be necessary to reduce the dose.

In patients with moderate renal impairment (CrCl 30-50 ml/min), it may be necessary to halve the dose and/or increase the intervals between doses.

In cases of severe renal impairment (CrCl < 30 ml/min), the use of colchicine is contraindicated (see section 4.3).

Hepatic impairment

In patients with mild to moderate hepatic impairment, no dose adjustment is required (see sections 4.4 and 5.2), although close monitoring for possible adverse effects is recommended. If adverse effects do occur, it may be necessary to reduce the dose.

Elderly patients and special populations

In elderly patients or those with renal or hepatic impairment, alternative therapies should be used. If colchicine is to be administered to these patients, the cumulative dose over a 4-day period must not exceed 3 mg, instead of the recommended adult dose of 6 mg (see section 4.2).

4.3. Contraindications

- - - - Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
      - Pregnancy
      - Severe renal impairment and haemodialysis patients.
      - Severe hepatic impairment
      - Severe gastrointestinal disorders
      - Stomach ulcer
      - Cardiac disorders
      - Haematological alterations, such as blood dyscrasias
      - For 14 days after using CYP3A4 and/or P-glycoprotein inhibitors.

4.4. Special warnings and precautions for use

- - - - If diarrhoea occurs, discontinue the medication or reduce the dose.
      - In elderly patients, children and debilitated or alcoholic patients, treatment with colchicine should be closely monitored because of the increased risk of cumulative toxicity in these populations.
      - Leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, aplastic anaemia and myelosuppression have been associated with the use of colchicine at therapeutic doses, so it is recommended that the patient should be monitored for side effects and have regular blood tests.
      - In patients with hepatobiliary and renal dysfunction, it may be necessary to adjust the dose. During treatment of the acute gout attack, the patient should be continuously monitored in case of renal or hepatobiliary dysfunction.
      - Colchicine is significantly excreted in the urine in healthy individuals. Colchicine clearance is decreased in patients with renal impairment. Total body clearance of colchicine is reduced by up to 75% in patients with kidney disease undergoing dialysis (see section 5.2).
      - Colchicine cannot be eliminated in patients undergoing dialysis so, a priori, its use is contraindicated (see section 4.3).
      - In patients with hepatic impairment, colchicine clearance may be significantly reduced and its plasma half-life increased.
      - Neuromuscular toxicity and rhabdomyolysis have been reported with chronic treatment at therapeutic doses. This risk may be increased in patients with renal impairment and in elderly patients (even those without renal and hepatic impairment).
      - Concomitant use of atorvastatin, simvastatin, pravastatin, fluvastatin, gemfibrozil, fenofibrate, fenofibric acid or bezafibrate (which themselves are associated with myotoxicity), digoxin or ciclosporin with colchicine may increase the occurrence of myopathies (see section 4.5). Once treatment with colchicine is discontinued, the symptoms usually disappear within a period of one week to several months.

4.5. Interaction with other medicinal products and other forms of interaction

Greater precaution should be taken when colchicine is combined with active substances that are metabolised by or interact with the cytochrome P450 system, in particular with the CYP3A4 isoenzyme or P-glycoprotein.

- - - - Anti-infective agents: colchicine toxicity is increased by simultaneous treatment with clarithromycin, erythromycin or telithromycin and CYP3A4 substrates and inhibitors, particularly in patients with pre-existing renal impairment. Other CYP3A4 inhibitors, such as itraconazole, ketoconazole, indinavir, nelfinavir, ritonavir and saquinavir, may increase colchicine toxicity.
        
        Calcium channel blockers: verapamil and diltiazem.
        
        Ciclosporin: colchicine should be used with caution in combination with ciclosporin due to the possible risk of increased neurotoxicity and myotoxicity.
        
        Vitamins: the absorption of Vitamin B12 may be altered by chronic or high-dose administration of colchicine. Vitamin requirements may be increased.

Concomitant use of atorvastatin, simvastatin, pravastatin, fluvastatin, gemfibrozil, fenofibrate, fenofibric acid or bezafibrate (which themselves are associated with myotoxicity) may increase the occurrence of myopathies. Once treatment with colchicine is discontinued, the symptoms usually disappear within a period of one week to several months.

Ingestion of grapefruit juice (which inhibits CYP3A4) should be avoided during treatment with colchicine, as it may increase the toxicity of colchicine.

4.6. Fertility, pregnancy and lactation

Pregnancy

No malformations or foetal/neonatal toxicity were observed after colchicine exposure in a limited number of pregnant women with familial Mediterranean fever. However, animal studies with colchicine have shown teratogenic effects. Therefore, as a precautionary measure due to the absence of controlled studies in humans and because it crosses the placenta, with the consequent risk to the foetus due to its mechanism of action, its use during pregnancy is contraindicated (see sections 4.3 and 5.3).

Breast-feeding

Colchicine is excreted in human milk.

Colchicine should not be used during breast-feeding.

Fertility

There are no data regarding the possible effects of colchicine on fertility.

4.7. Effects on ability to drive and use machines

This medicine has not been reported to have any effect on the ability to drive and use machines.

4.8. Undesirable effects

Common adverse reactions that have been reported include nausea, vomiting and abdominal pain. High doses may cause severe diarrhoea, gastrointestinal bleeding, skin rashes and hepatic or renal impairment.

Peripheral neuropathy, myopathy, rhabdomyolysis, alopecia and azoospermia have occurred occasionally, and with prolonged treatment there can be bone marrow failure with agranulocytosis, thrombocytopenia and aplastic anaemia.

Treatment should be discontinued and the patient should go to an emergency department at the first symptom of nausea, vomiting, abdominal pain or diarrhoea.

According to the AGREE study (see section 5.1), in which 185 patients with acute gout attack were allocated to three different treatment groups: high-dose colchicine treatment [1.2 mg followed by 0.6 mg every hour for 6 hours (total: 4.8 mg)], low-dose treatment [1.2 mg followed by 0.6 mg in the next hour (total: 1.8 mg)] and placebo treatment, the incidence of adverse reactions in the different groups was 76.9%, 36.5% and 27.1%, respectively. The incidence of the most frequently reported adverse reactions is detailed below. Colchicine dose: Adverse reactions: High Dose (n=52): 40 (76.9), Low Dose (n=74): 27 (36.5), Placebo (n=59): 16 (27.1); OR (95% CI): High dose vs

Placebo: 9.0 (3.8-21.2), Low dose vs Placebo: 1.5 (0.7-3.2), High dose vs Low dose: 5.8 (2.6-12.9). Gastrointestinal adverse reactions: High Dose (n=52): 40 (76.9), Low Dose (n=74): 19 (25.7), Placebo (n=59): 12 (20.3); OR (95% CI): High dose vs Placebo: 13.1 (5.3-32.3), Low dose vs Placebo: 1.4 (0.6-3.1), High dose vs Low dose: 9.6 (4.2-22.1).

Diarrhoea: High Dose (n=52): 40 (76.9), Low Dose (n=74): 17 (23.0), Placebo (n=59): 8 (13.6); OR (95% CI): High dose vs Placebo: 21.3 (7.9-56.9), Low dose vs Placebo: 1.9 (0.8-4.8), High dose vs Low dose: 11.2 (4.8-25.9). Nausea: High Dose (n=52): 9 (17.3), Low Dose (n=74): 3 (4.1), Placebo (n=59): 3 (5.1); OR (95% CI): High dose vs Placebo: 3.9 (1.0-15.3), Low dose vs

Placebo: 0.8 (0.2-4.1), High dose vs Low dose: 11.2 (4.8-25.9). Vomiting: High Dose (n=52): 9 (17.3), Low Dose (n=74): 0 (0), Placebo (n=59): 0 (0). Severe adverse reactions: High Dose (n=52): 10 (19.2), Low Dose (n=74): 0 (0), Placebo (n=59): 1 (1.7); OR (95% CI): High dose vs Placebo: 13.8 (1.7-112). Diarrhoea: High Dose (n=52): 10 (19.2), Low Dose (n=74): 0 (0),

Placebo (n=59): 0 (0). Melaena: High Dose (n=52): 1 (1.92), Low Dose (n=74): 0 (0), Placebo (n=59): 0 (0). Nausea: High Dose (n=52): 1 (1.92), Low Dose (n=74): 0 (0), Placebo (n=59): 0 (0). Gout: High Dose (n=52): 0 (0), Low Dose (n=74): 0 (0), Placebo (n=59): 1 (1.7). Reporting of suspected adverse reactions.

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Spanish Pharmacovigilance System of Medicines for Human Use: www.notificaRAM.es.

4.9. Overdose

Colchicine has a narrow therapeutic index and is extremely toxic in case of overdose.

High-risk patients are those with hepatic or renal impairment, gastrointestinal or cardiac disorders and elderly patients.

Because colchicine overdose is complex, specialist advice should be obtained rapidly to manage the overdose as promptly as possible.

The exact dose of colchicine that causes significant toxicity is unknown. Deaths have been reported after ingestion of doses as low as 7 mg over a 4-day period, while there are cases of patients who survived taking doses of more than 60 mg.

From a review of 150 overdose patients, it has been established that those who ingested a dose lower than 0.5 mg/kg survived, with a milder toxicity profile, while subjects who took doses between 0.5 and 0.8 mg/kg experienced more severe reactions, including myelosuppression. There was a 100% mortality rate in subjects who ingested more than 0.8 mg/kg.

There may be a delay of up to 6 hours before toxicity becomes apparent and some signs may even be delayed for up to a week or more. Therefore, any patient with suspected overdose, even without apparent signs, should seek specialist medical attention immediately.

The first signs of acute colchicine toxicity usually appear approximately 24 hours after ingestion. The most common symptoms include burning sensation and discomfort in the mouth and throat, difficulty swallowing, digestive disorders such as diffuse abdominal pain, nausea, vomiting, tenesmus, severe diarrhoea (in some cases bloody), resulting in dehydration (metabolic acidosis) and circulatory disorders (hypotension), which together can lead to hypovolaemic shock. Peripheral leukocytosis has occasionally been observed.

After the first 24 hours and for up to 7 days, the signs of toxicity include confusion, alopecia, cardiac disorders (including arrhythmias and decreased cardiac output), renal and hepatic impairment, respiratory distress, hyperpyrexia and bone marrow suppression. These signs may progress to multi-organ failure accompanied by bone marrow aplasia, CNS toxicity, seizures, coma, hepatocellular damage, rhabdomyolysis, respiratory distress, renal and cardiac damage and disseminated intravascular dissemination. Death is generally due to cardiorespiratory depression.

Patients who survive beyond 7 days after an overdose may experience alopecia, rebound leukocytosis and stomatitis (about 10 days after the overdose).

Treatment:

Treatment of colchicine overdose should include the use of oral activated charcoal in adults who have ingested more than 0.1 mg/kg of body weight of colchicine during the one-hour period following its ingestion and also in children who have ingested any amount during a one-hour period. Higher doses of activated charcoal may increase systemic elimination and may be considered in patients who have ingested more than 0.3 mg/kg of body weight.

There is no specific antidote for colchicine. Gastric lavage may be performed. Haemodialysis and haemoperfusion do not increase the elimination of colchicine. Treatment of overdose should include general supportive and symptomatic measures depending on the patient’s clinical condition, including monitoring of vital signs, ECG, haematological and biochemical values. Breathing assistance may be required. Circulation should be maintained and the water-electrolyte balance should be corrected. In case of severe abdominal pain, 10 mg of morphine sulphate may be administered intramuscularly.

To aid with the management of delayed onset of symptoms, patients should be monitored carefully for at least 6 hours after overdose, or at least 12 hours if they have taken more than 0.3 mg/kg of body weight. After this time, asymptomatic patients can be discharged with the warning that if they notice gastrointestinal symptoms, they should return to the unit where they were treated.

5 - PHARMACOLOGICAL PROPERTIES

5.1. Pharmacodynamic properties

Pharmacotherapeutic group: Antigout preparations. Preparations with no effect on uric acid metabolism.

ATC code: M04AC01

Colchicine is used for the relief of acute gout attacks and prophylaxis of acute flares. Colchicine is also indicated for the treatment of chronic gout and familial Mediterranean fever.

The mechanism of action of colchicine is not fully understood. Colchicine produces an immediate response in gout attacks, probably by reducing the inflammatory reaction caused by urate crystals. This effect is due to several actions, including a reduction in leukocyte motility.

Colchicine inhibits phagocytosis of urate microcrystals, with a reduction in lactic acid production, which maintains a normal local pH. Acidity favours the precipitation of urate crystals, which is what causes gout attacks.

Colchicine has no analgesic activity and no effect on plasma concentrations or elimination of uric acid.

It also has antimitotic activity (stops or inhibits cell division in the metaphase and anaphase).

Colchicine has other pharmacological actions in animals: it alters neuromuscular function, increases gastrointestinal activity by neurogenic stimulation, increases sensitivity to CNS depressants, increases response to sympathomimetics, depresses the central respiratory centre, produces vasoconstriction, causes hypertension by central vasomotor stimulation and decreases body temperature.

The AGREE (Acute Gout Flare Receiving Colchicine Evaluation) study, a multi-centre, double-blind, placebo-controlled trial, evaluated the proportion of patients who responded to the following colchicine treatment regimens:

- - - - Group 1: High-dose colchicine (1.2 mg followed by 0.6 mg/hour for 6 hours [total dose: 4.8 mg])
        
        Group 2: Low-dose colchicine (1.2 mg followed by 0.6 mg/hour for 1 hour [1.8 mg])
        
        Group 3: Placebo

A total of 184 patients were included in the intention-to-treat analysis. The primary endpoint of the study was the proportion of patients who responded to treatment. A responder was defined as a patient with a ≥ 50 % reduction in pain perception within the 24 hours after the first dose of medication, without using rescue medication. In the low-dose group, 28 out of 74 people (37.8%) responded to treatment; in the high-dose group, 17 out of 52 patients (32.7%) responded to treatment; and in the placebo group, 9 out of 58 patients (15.5%) were responders (p=0.005 and p=0.034, respectively, vs placebo). During the first few hours of treatment, 23 patients (31.1%) took rescue medication in the low-dose group (p=0.027 vs placebo), 18 patients (34.6%) in the high-dose group (p=0.103 vs placebo), and 29 patients (50%) in the placebo group. The low-dose
group showed a similar adverse effect profile to the placebo group, with an Odds Ratio (OR) of 1.5 (95% confidence interval [95% CI]: 0.7-3.2).

High-dose colchicine was significantly associated with diarrhoea, vomiting and other adverse effects compared to the use of low-dose colchicine or placebo.

In the high-dose group, 40 patients (76.9%) experienced diarrhoea (OR 21.3 [95% CI: 7.9-56.9]), 10 (19.2%) severe diarrhoea and 9 (17.3%) vomiting. In the low-dose colchicine group, 23.0% of the patients experienced diarrhoea (OR 1.9 [95% CI: 0.84-8]) and none had severe diarrhoea or vomiting.

Low-dose colchicine resulted in a maximum plasma concentration and efficacy comparable to high-dose colchicine for the treatment of acute gout attack, with a similar safety profile to placebo.

5.2. Pharmacokinetic properties

Colchicine is absorbed orally with an approximate bioavailability of 45%.

Approximately 39% binds to albumin and there is no direct relationship with concentration.

It binds to all tissues, primarily the intestinal mucosa, liver, kidneys and spleen, with the exception of the myocardium, skeletal muscles and lungs.

It has been reported that colchicine crosses the placenta, and plasma levels in the foetus are approximately 15% of the maternal concentration. The concentration in breast milk is similar to the plasma concentration observed in the mother.

The mean volume of distribution can range from 2 to 8 l/kg.

Colchicine is partially metabolised in the liver by demethylation to two major metabolites, 2-O-desmethylcolchicine and 3-O-desmethylcolchicine, and one minor metabolite, 10-O-desmethylcolchicine. CYP3A4 is involved in the metabolism of colchicine. Plasma levels of the two major metabolites are less than 5% of those of colchicine.

The pharmacological activity of these metabolites is unknown.

Colchicine and its metabolites undergo enterohepatic circulation.

In patients with severe hepatic impairment, its clearance is significantly decreased and its half-life is prolonged.

In patients with mild to moderate hepatic impairment, the data show a high degree of inter-patient variability.

Renal clearance of colchicine has been estimated to be 0.727 l/h/kg in patients with good renal function. In patients with severe renal impairment, renal clearance was reduced by 75%. There are no data in patients with mild to moderate renal impairment.

Colchicine is not eliminated by haemodialysis.

The elimination half-life in healthy volunteers described in the literature (aged between 25 and 28 years) ranges from 26.6 to 31.2 hours.

Colchicine is a P-glycoprotein substrate.

No differences in pharmacokinetics have been described according to sex.

The pharmacokinetics in paediatric patients have not been described.

According to a published study in elderly patients, the mean plasma peak and AUC were twice as high as in young subjects. The explanation for this difference may be lower renal function.

5.3. Preclinical safety data

Available non-clinical data did not show any risks in humans other than those expected based on the established conditions of administration. However, colchicine was found to be teratogenic in animals.

6 - PHARMACEUTICAL PARTICULARS

6.1. List of excipients

Calcium hydrogen phosphate dihydrate

Microcrystalline cellulose

Anhydrous colloidal silica

Magnesium stearate

6.2. Incompatibilities

Not applicable.

6.3. Shelf life

3 years

6.4. Special precautions for storage

This medicine does not require any special storage conditions.